The content on this site is intended for healthcare professionals only
Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma.
Similar to bortezomib, but administered orally, MLN9708 is the first oral drug to go into clinical trial for myeloma. MLN9708 is boron-based making it a reversible inhibitor.
Current trials using the experimental drug aim to determine the dosage and efficacy in myeloma. Patients receiving the drug have already been heavily treated with commonly available agents and had high efficacy, with very low rates of neuropathy, when used in combination with other drugs.
en Español
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL
